Prelude Therapeutics and Merck Announce Clinical Collaboration to Evaluate PRT3789 with KEYTRUDA® in SMARCA4-Mutated Cancers.
Therapeutics Company Announces Major Clinical Collaboration With Merck
Therapeutics Company Announces Major Clinical…
Therapeutics Company Announces Major Clinical Collaboration With Merck
Prelude Therapeutics and Merck Announce Clinical Collaboration to Evaluate PRT3789 with KEYTRUDA® in SMARCA4-Mutated Cancers.